

1
2
3
4
5
6
7
8
9
10
11
12

Comparison of the Effects of Open and Closed Endotracheal Suction Systems on Ventilator-Associated Pneumonia and Mortality

ABSTRACT

Aims: Nosocomial pneumonia is a prevalent complication in patients admitted to intensive care units. Endotracheal suction (ES) is used to clean the airways of secretions in patients under mechanical ventilation (MV). The objective of this study was to compare the effects of an open endotracheal suction system (OESS) versus a closed endotracheal suction system (CESS) on the incidence of ventilator-associated pneumonia (VAP).

Study Design: Retrospective examination of hospital records.

Place and Duration of Study: Reanimation Intensive Care Unit, Van Training and Research Hospital, Van, Turkey, between January 2018 and December 2019.

Methodology: Age, gender, and length of stay in the intensive care unit and under mechanical ventilation (MV), mortality and isolated microorganism status of 73 (35.6%) patients with VAP were analyzed retrospectively. These features were compared according to the ES type applied. Sample: The study was conducted among 205 patients who were connected to a mechanical ventilator for more than 48 h in the reanimation intensive care unit (RICU) of a tertiary care hospital.

Results: There was no difference between OESS and CESS groups in terms of mortality rates, length of stay in the RICU, and duration of MV. There was a significant difference in terms of incidence of VAP between the OESS group and the CESS group (41.8% and 29%, respectively; $P = .045$) *Acinetobacter baumannii* was the most frequently isolated microorganism in both groups.

Conclusion: CESS treatment was associated with a lower incidence of VAP in patients of the RICU.

Keywords: ventilator-associated pneumonia; intensive care unit; suction; mechanical ventilation

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

1. INTRODUCTION (ARIAL, BOLD, 11 FONT, LEFT ALIGNED, CAPS)

Nosocomial pneumonia (NP) is one of the most common complications in intensive care units.[1-3] Mechanical ventilation (MV) and endotracheal suction (ES) are accepted as predisposing factors for NP, and the clinical condition of NP patients is defined as ventilator-associated pneumonia (VAP).[4] Patients who are intubated and treated with MV are almost

31 10 times more likely to develop NP than patients with spontaneous breathing.[5] Additionally,
32 VAP is associated with high morbidity and mortality due to the challenges in its diagnosis
33 and treatment.[6]

34 The endotracheal tube disrupts tissue integrity in the respiratory tract, increases secretion,
35 and eliminates the cough reflex. In patients with weakened natural defense mechanisms, the
36 lower respiratory tract is susceptible to infection through aspiration of nasopharyngeal
37 bacterial colonies.[7, 8] Therefore, one of the most important methods to reduce the
38 incidence of VAP during MV is tracheal aspiration. Adequate oxygenation is also ensured
39 while using ES to remove secretions, which are the main source of infection in the
40 respiratory tract.[9, 10]

41 Endotracheal suction is performed using two main types of systems: open and closed. In an
42 open endotracheal suction system (OESS), ES is typically performed after the patient has
43 been disconnected from MV. However, this disconnection can lead to hypoxia, decreased
44 humidity, and reduced positive end-expiratory pressure. Consequently, a closed
45 endotracheal suction system (CESS) has been introduced to minimize these effects. In a
46 CESS, an additional instrument is utilized to insert the suction catheter through the
47 endotracheal tube without disconnecting the patient from MV. This approach is aimed at
48 preventing hypoxia, minimizing loss in lung volume, and reducing environmental and
49 personnel-related contamination.[11]

50 While the goal is to minimize the risk of contamination, the literature reports varying results
51 regarding which suction method achieves lower infection rates and reduced morbidity and
52 mortality.[7, 10, 12] In this study, we aimed to compare the incidence of VAP in our intensive
53 care patients who transitioned from an OESS to a CESS.

54

55 **2. MATERIAL AND METHODS**

56

57 **The study was conducted using retrospective data analysis from patients in a 20-bed**
58 **reanimation intensive care unit (RICU) of a tertiary hospital.**

59 In this study, we analyzed data from patients who received MV in the intensive care unit for
60 at least 48 hours between January 2018 and December 2019. **A total of 203 patients** were
61 included in the study after we identified and excluded those with known chronic respiratory
62 diseases, terminal malignancies, and previous diagnoses of NP.

63 Prior to the RICU's transition to a CESS in February 2019, **110 patients** connected to MV
64 underwent OESS treatment. CESS treatment was applied to **93 patients** after the transition.

65 During the ES, nurses routinely implemented barrier precautions, including handwashing
66 and the use of gloves and masks. In the OESS, the connection between the tracheal tube
67 and the mechanical ventilator was disconnected, and suction was performed using an
68 aspiration catheter passed through the tracheal tube. A different aspiration catheter was
69 used for each suction. A system manufactured by TUORen, MedNet, China, was selected
70 for endotracheal aspiration in the CESS. Before the patient was disconnected from the
71 mechanical ventilator, one end of the closed suction catheter was connected to the
72 mechanical ventilator and tracheal tube, and the other end was connected to the suction
73 tube. After the catheter valve was opened, suction was performed using a Nelaton catheter
74 placed in the tracheal tube.

75 The diagnostic criteria for VAP were determined as follows: the presence of new or
76 persistent infiltrations, cavitations, or consolidations on chest X-rays, in addition to at least

77 two of the microbiological and clinical criteria (body temperature > 38 °C or < 36 °C; white
78 blood cell count > 10,000 mm³ or < 5,000 mm³; and purulent tracheobronchial secretions
79 and gas degradation).[13] After VAP was diagnosed, appropriate antibiotic treatments were
80 determined based on the growth in endotracheal aspirate cultures from the patients.

81 Information recorded for patients in the intensive care unit who underwent MV and were
82 diagnosed with VAP included age, gender, Chronic Health Evaluation II (APACHE II) scores
83 at the time of MV initiation, length of stay in the intensive care unit, MV duration, and
84 mortality status. Microorganisms identified in endotracheal aspirate cultures from VAP
85 patients were also recorded.

86 This study was conducted with approval from the ethics committee of Van Research and
87 Training Hospital on 10/09/2020 (Approval Number: 2020/18).

88

89 2.1 Statistical Analysis

90

91 We utilized analytical methods to evaluate the normal distribution of continuous variables. In
92 the descriptive findings, categorical variables are given as numbers (percentages), and
93 continuous variables are represented as a mean ± standard deviation (SD) for normal
94 scattering data and a median (interquartile range, IQR) for normal nonscattering data. For
95 the categorical variables, the statistical difference among the groups was determined using
96 chi-square tests. For the continuous variables, the statistical difference among the groups
97 was determined using the Mann–Whitney U test. Statistical significance was accepted as $p < 0.05$. RStudio version 3.6.3 was employed for the statistical analysis of research data.

98

100 3. RESULTS AND DISCUSSION

101

102 A total of 203 patients were mechanically ventilated in the RICU between January 2018 and
103 December 2019.

104 An OESS was applied to 110 patients who were mechanically ventilated between January
105 2018 and February 2019. VAP was detected in 46 (41.8%) of these patients. Between
106 February 2019 and December 2019, a CESS was applied to 93 patients who were
107 mechanically ventilated. VAP was detected in 27 (29%) of these patients. There was a
108 significant difference in the detection of VAP between the two groups that underwent OESS
109 and CESS treatment ($P = 0.045$) (Table 1).

110

111 Patient characteristics such as age, gender, and APACHE II scores at the time of MV were
112 evaluated. The results of the two groups were compared. There was no significant difference
113 between the two groups in terms of patient characteristics (Table 2).

114

115

116

117

118 **Table 1. Comparison of the incidence of VAP between patient groups that underwent**
119 **by OESS and CESS treatment**

120

Ventilator Associated Pneumonia	OESS n(%)	CESS n(%)	P
Yes	46 (41.8%)	27 (28.4%)	.045
No	64 (58.2%)	68 (71.6%)	

Total	110 (100%)	95 (100%)
-------	------------	-----------

121
122
123
124

Table 2. Comparison of patient characteristics between patient groups diagnosed with VAP

	Open Endotracheal Suction System	Closed Endotracheal Suction System	<i>P</i>
Age median(IQR)	74.5 (60.5-81.75)	70 (55-79)	.148
Gender			.290
Female n(%)	18 (39.1%)	14 (51.9%)	
Male n(%)	28 (60.9%)	13 (48.1%)	
APACHE II mean (SD)	23.78 (5,1)	25.67 (6.31)	.129

125 *APACHE II: Chronic Health Evaluation II scores*
126 *SD: Standard deviation*
127 *IQR: I nter Quantile Range*

128
129
130
131
132
133

The two groups of patients who were diagnosed with VAP and underwent OESS or CESS treatment were evaluated according to the stay in the intensive care unit, duration of the MV treatment, and mortality status, and then the two groups were compared. There was no significant difference between the two groups in terms of the stay in the intensive care unit, duration of MV treatment, or mortality status (Table 3).

134
135
136
137
138

Microorganisms grown in endotracheal aspirate cultures from patients diagnosed with VAP were recorded. *Acinetobacter baumannii* was the most isolated in both groups; it was isolated in 31 (67.4%) patients in the OESS group and in 13 (48.2%) patients in the CESS group. The two groups were compared in terms of microorganism distribution as *Acinetobacter baumannii* and other microorganisms (Table 4).

139
140
141
142
143
144
145
146

The most important causes of pneumonia in patients receiving MV are contamination of the lower respiratory tract from the pharynx and intestine through the endotracheal tube cuff or direct cross-contamination from nurses and other healthcare professionals.[14] Theoretically, CESS treatment should reduce the incidence of VAP because it minimizes personnel-related contamination and prevents open contact of the endotracheal tube, which creates a direct passageway between the lower respiratory tract and the environment. However, there are notably different results in the literature regarding the effects of the OESS and CESS on VAP.[1, 15, 16]

147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162

Ardehalli et al. reported that the ES type had no effect on the incidence of VAP.[17] Similarly, a prospective study with a relatively high participation of patients from four centers revealed that the type of ES did not affect gram-negative bacteria grown in endotracheal aspirate cultures.[18] Based on the theory that the ES type can change the incidence of VAP in different age groups, this difference could not be demonstrated in another study conducted in pediatric intensive care patients.[19] Meta-analysis studies were also conducted because strong assessments could not be formed from the number of patient groups receiving MV therapy at the centers between certain dates. In their systematic review, which included 16 clinical studies, Subirana et al. concluded that the incidence of VAP did not change with these two systems.[20] There are additional meta-analyses supporting that study.[21, 22] In contrast to expectations, some studies show that CESS does not change VAP frequency, whereas some studies report a higher incidence of VAP in patients who underwent OESS treatment.[17, 23] In a prospective randomized study of 200 patients, David et al. found that CESS significantly reduced the incidence of VAP, as the authors expected.[24] In a study conducted on a specific group of patients, the authors found that CESS in head trauma patients minimized the contamination of the patients' lower airways, thus reducing the

163 incidence of VAP.[25] Furthermore, Sanaie et al. reported that OESS increased the
 164 frequency of VAP in their meta-analysis, which included 10 studies, and recommend the use
 165 of CESS in intensive care units, if possible.[26] Our study supports these results.

166

167 **Table 3. Comparison of hospital stay, MV duration, and mortality rate between the**
 168 **patient groups diagnosed with VAP**

169

	Open Endotracheal Suction System median(IQR)	Closed Endotracheal Suction System median(IQR)	<i>P</i>
Length of Hospital Stay	31 (12.75-50.5)	34 (16-84)	.192
Length of Mechanical Ventilation	24 (12-49.75)	33 (13-80)	.293
Mortality n(%)	22 (47.8%)	12 (44.4%)	.524

170

171

172

173

174

IQR: I nter Quantile Range

172 **Table 4. Comparison of microorganism distribution between patient groups**
 173 **diagnosed with VAP**

	Open Endotracheal Suction System n(%)	Closed Endotracheal Suction System n(%)	<i>P</i>
Acinetobacter species	31 (67.4%)	13 (48.2%)	.169
Others			
E. Coli	2 (4.3%)	2 (7.4%)	
Klebsiella spp.	8 (17.4%)	5 (18.5%)	
Pseudomonas spp.	3 (6.6%)	5 (18.5%)	
Staphylococcus aureus	2 (4.3%)	0	
Serratia marcescens	0	2 (7.4%)	

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

The varying results and interpretations in the literature can be attributed to several factors. One of these factors may be healthcare professionals, who are a significant cause of contamination in intensive care units. The educational backgrounds of nurses, especially aspirants, may differ across clinics. There may be nurses with insufficient knowledge of the principles of CESS practice.[17] In addition, preexisting lower respiratory tract diseases in patients, insufficient or small sample sizes, and inappropriate inclusion or exclusion criteria in study design may result in different findings. The authors of other studies attributed the inconsistent results to several factors: the VAP diagnosis criteria differed across the studies; the studies were composed of patients in different intensive care units (surgical, medical, neurosurgical, and trauma); the patient groups were not homogeneous in terms of underlying diseases; it was not known whether the CESS was changed, even though companies recommended it; and the empirical treatments were not known.[17, 26, 27] Since the advantage of the CESS in VAP development has not been clearly demonstrated, its use is not yet recommended for VAP. However, some guidelines recommend CESS use for cost and safety reasons.[12, 28, 29]

192

193

194

195

196

197

198

During OESS use, a short-term hypoxia is expected, and vital values will deteriorate due to the patient's disconnection from the mechanical ventilator. Additionally, the intensive care unit stay, MV duration, and mortality rates are expected to be negatively affected due to the possible increase in the frequency of VAP and changes in vital signs. However, no significant results could be found in the literature to demonstrate the distinct superiority of CESS in this regard. Sayed et al. reported no difference in mortality rates, although they observed that vital signs were more impaired in patients who underwent OESS treatment in

199 their study.[30] Furthermore, Combes et al., Topeli et al., Ozcan et al., and Hamishkar et al.
200 found that the MV duration and mortality rates of the two systems were similar in their
201 respective studies.[15, 16, 31, 32] In addition, two studies, one of which was a meta-
202 analysis, showed that the two systems had no impact on the length of stay in intensive care
203 nor the mortality rate.[17, 26]

204 *Acinetobacter baumannii* was found to be the most common agent isolated in endotracheal
205 aspirate cultures from patients diagnosed with VAP in our study. Ardehali et al. and Tamura
206 et al. also reported *Acinetobacter* species (72.7% and 97.6%, respectively) as the most
207 common causative agent.[17, 33] In other studies, *Acinetobacter* species may be lag in
208 terms of incidence.[34-36] Different microbiota in hospitals, the faster spread of some
209 bacterial species, and different methods of sample collection for microbiological testing may
210 produce different microbiological results.

211 There were several important limitations to our study. The most important limitation is that
212 the study included biases arising from its retrospective nature. In addition, because it is a
213 single-center study, it does not include the large number of patients found in most other
214 studies. The study design did not include patients' reasons for admission to the intensive
215 care unit, their additional comorbidities, or their reasons for receiving MV therapy. These
216 factors can affect patient mortality rates. By examining the changes in patients' vital signs,
217 the effect of ES type on vital signs could also be evaluated.

218 219 **4. CONCLUSION**

220
221 Our results showed that CESS treatment decreased the incidence of VAP but that neither
222 system is superior in reducing mortality rates and duration of treatment. Selection can be
223 made considering intensive care conditions, the individual patient's disease, and cost. To
224 obtain stronger conclusions, we recommend high-quality prospective and multicenter trials
225 with larger sample sizes

226 **COMPETING INTERESTS**

227
228 Authors have declared that no competing interests exist.

229 230 **AUTHORS' CONTRIBUTIONS**

231
232 'Author A' designed the study, performed the statistical analysis, wrote the protocol, and
233 wrote the first draft of the manuscript. 'Author B' managed the analyses of the study and the
234 literature searches. All authors read and approved the final manuscript.

235 236 **ETHICAL APPROVAL**

237
238 All authors hereby declare that all experiments have been examined and approved by the
239 ethics committee of Van Research and Training Hospital on 10/09/2020 (Approval Number
240 2020/18) and have therefore been performed in accordance with the ethical standards
241 enacted in the 1964 Declaration of Helsinki.

242 243 **REFERENCES**

244
245 1. Alipour N, Manouchehrian N, Sanatkar M, Anvari HMP, Jahromi MSS. Evaluation of
246 the effect of open and closed tracheal suction on the incidence of ventilator associated
247 pneumonia in patients admitted in the intensive care unit. *Archives of Anesthesiology and*
248 *Critical Care*. 2016;2(2):193-6.

- 249 2. Gadani H, Vyas A, Kar AK. A study of ventilator-associated pneumonia: Incidence,
250 outcome, risk factors and measures to be taken for prevention. *Indian journal of*
251 *anaesthesia*. 2010;54(6):535.
- 252 3. Vanhems P, Bénet T, Voirin N, Januel J-M, Lepape A, Allaouchiche B, et al. Early-
253 onset ventilator-associated pneumonia incidence in intensive care units: a surveillance-
254 based study. *BMC infectious diseases*. 2011;11:1-6.
- 255 4. Kózka M, Segá A, Wojnar-Gruszka K, Tarnawska A, Gniadek A. Risk factors of
256 pneumonia associated with mechanical ventilation. *International Journal of Environmental*
257 *Research and Public Health*. 2020;17(2):656.
- 258 5. Juneja D, Javeri Y, Singh O, Nasa P, Pandey R, Uniyal B. Comparing influence of
259 intermittent subglottic secretions drainage with/without closed suction systems on the
260 incidence of ventilator associated pneumonia. *Indian Journal of Critical Care Medicine: Peer-*
261 *reviewed, Official Publication of Indian Society of Critical Care Medicine*. 2011;15(3):168.
- 262 6. Kandeel N, Tantawy N. Current nursing practice for prevention of ventilator
263 associated pneumonia in ICUs. *Life Science Journal*. 2012;9(3):966-73.
- 264 7. Pagotto IM, Oliveira LRdC, Araújo FC, Carvalho NAAd, Chiavone P. Comparison
265 between open and closed suction systems: a systematic review. *Revista Brasileira de*
266 *terapia intensiva*. 2008;20:331-8.
- 267 8. Makhnevich A, Feldhamer KH, Kast CL, Sinvani L. Aspiration pneumonia in older
268 adults. *Journal of Hospital Medicine*. 2019;14(7):429-35.
- 269 9. Coelho L, Moniz P, Guerreiro G, Póvoa P. Airway and Respiratory Devices in the
270 Prevention of Ventilator-Associated Pneumonia. *Medicina*. 2023;59(2):199.
- 271 10. Jongerden IP, Rovers MM, Grypdonck MH, Bonten MJ. Open and closed
272 endotracheal suction systems in mechanically ventilated intensive care patients: a meta-
273 analysis. *Critical care medicine*. 2007;35(1):260-70.
- 274 11. Siempos I, Vardakas K, Falagas M. Closed tracheal suction systems for prevention
275 of ventilator-associated pneumonia. *British journal of anaesthesia*. 2008;100(3):299-306.
- 276 12. Dodek P, Keenan S, Cook D, Heyland D, Jacka M, Hand L, et al. Evidence-based
277 clinical practice guideline for the prevention of ventilator-associated pneumonia. *Annals of*
278 *Internal Medicine*. 2004;141(4):305-13.
- 279 13. Society AT, America IDSo. Guidelines for the management of adults with hospital-
280 acquired, ventilator-associated, and healthcare-associated pneumonia. *American journal of*
281 *respiratory and critical care medicine*. 2005;171(4):388.
- 282 14. Mahmoodpoor A, Peyrovi-far A, Hamishehkar H, Bakhtyari Z, Mirinezhad MM,
283 Hamidi M, et al. Comparison of prophylactic effects of polyurethane cylindrical or tapered
284 cuff and polyvinyl chloride cuff endotracheal tubes on ventilator-associated pneumonia. *Acta*
285 *Medica Iranica*. 2013:461-6.
- 286 15. Hamishekar H, Shadvar K, Taghizadeh M, Golzari SE, Mojtahedzadeh M,
287 Soleimanpour H, et al. Ventilator-associated pneumonia in patients admitted to intensive

- 288 care units, using open or closed endotracheal suctioning. *Anesthesiology and pain medicine*.
289 2014;4(5).
- 290 16. Topeli A, Harmanci A, Cetinkaya Y, Akdeniz S, Unal S. Comparison of the effect of
291 closed versus open endotracheal suction systems on the development of ventilator-
292 associated pneumonia. *Journal of Hospital Infection*. 2004;58(1):14-9.
- 293 17. Ardehali SH, Fatemi A, Rezaei SF, Forouzanfar MM, Zolghadr Z. The effects of
294 open and closed suction methods on occurrence of ventilator associated pneumonia; A
295 comparative study. *Archives of academic emergency medicine*. 2020;8(1).
- 296 18. Jongerden IP, Buiting AG, Leverstein-van Hall MA, Speelberg B, Zeidler S,
297 Kesecioglu J, et al. Effect of open and closed endotracheal suctioning on cross-transmission
298 with Gram-negative bacteria: a prospective crossover study. *Critical care medicine*.
299 2011;39(6):1313-21.
- 300 19. Morrow BM, Mowzer R, Pitcher R, Argent AC. Investigation into the effect of closed-
301 system suctioning on the frequency of pediatric ventilator-associated pneumonia in a
302 developing country. *Pediatric Critical Care Medicine*. 2012;13(1):e25-e32.
- 303 20. Subirana M, Solà I, Benito S. Closed tracheal suction systems versus open tracheal
304 suction systems for mechanically ventilated adult patients. *Anesthesia and analgesia*.
305 2008;106(4):1326-.
- 306 21. Overend TJ, Anderson CM, Brooks D, Cicutto L, Keim M, McAuslan D, et al.
307 Updating the evidence base for suctioning adult patients: A systematic review. *Canadian*
308 *respiratory journal*. 2009;16:e6-e17.
- 309 22. Niel-Weise B, Snoeren R, Van den Broek P. Policies for endotracheal suctioning of
310 patients receiving mechanical ventilation: a systematic review of randomized controlled
311 trials. *Infection Control & Hospital Epidemiology*. 2007;28(5):531-6.
- 312 23. Ebrahimi Fakhar HR, Rezaie K. Effect of closed endotracheal suction on incidence
313 of ventilator-associated pneumonia. *Scientific Journal of Kurdistan University of Medical*
314 *Sciences*. 2010;15(2):79-87.
- 315 24. David D, Samuel P, David T, Keshava SN, Irodi A, Peter JV. An open-labelled
316 randomized controlled trial comparing costs and clinical outcomes of open endotracheal
317 suctioning with closed endotracheal suctioning in mechanically ventilated medical intensive
318 care patients. *Journal of critical care*. 2011;26(5):482-8.
- 319 25. Alipour N, Toulabi T, Manouchehrian N, Anbari K, Rahimi Bashar F. A comparison
320 of the effect of open and closed endotracheal suctioning on hemodynamic status of patients
321 in the ICU. *Evidence Based Care*. 2014;3(4):65-74.
- 322 26. Sanaie S, Rahnemayan S, Javan S, Shadvar K, Saghaleini S-H, Mahmoodpoor A.
323 Comparison of Closed vs Open Suction in Prevention of Ventilator-associated Pneumonia: A
324 Systematic Review and Meta-analysis. *Indian Journal of Critical Care Medicine: Peer-*
325 *reviewed, Official Publication of Indian Society of Critical Care Medicine*. 2022;26(7):839.
- 326 27. Mulla RJ, Mohite VR. Efficacy of closed and open endotracheal suction on
327 prevention of ventilator-associated pneumonia on patients admitted to critical care unit at

- 328 tertiary care hospital. Journal of Datta Meghe Institute of Medical Sciences University.
329 2023;18(2):192-8.
- 330 28. Restrepo R, Brown J, Hughes J. AARC Clinical Practice Guidelines. Endotracheal
331 suctioning of mechanically ventilated patients with artificial airways 2010. 2010.
- 332 29. Muscedere J, Dodek P, Keenan S, Fowler R, Cook D, Heyland D, et al.
333 Comprehensive evidence-based clinical practice guidelines for ventilator-associated
334 pneumonia: prevention. Journal of critical care. 2008;23(1):126-37.
- 335 30. Ahmed Sayed Z. Effect of open versus closed suction system on cardiorespiratory
336 parameters and suction duration among critically ill mechanically ventilated patients.
337 Egyptian Journal of Health Care. 2019;10(2):409-18.
- 338 31. Combes P, Fauvage B, Oleyer C. Nosocomial pneumonia in mechanically ventilated
339 patients, a prospective randomised evaluation of the Stericath closed suctioning system.
340 Intensive care medicine. 2000;26:878-82.
- 341 32. Ozcan MS, Bonett SW, Martin AD, Gabrielli A, Layon AJ, Banner MJ. Abnormally
342 increased power of breathing as a complication of closed endotracheal suction catheter
343 systems. Respiratory care. 2006;51(4):423-5.
- 344 33. Tamura Y, Kumamaru H, Abe K, Satoh T, Miyata H, Ogawa A, et al. Microorganisms
345 and clinical outcomes of early-and late-onset ventilator-associated pneumonia at Srinagarind
346 Hospital, a tertiary center in Northeastern Thailand. 2020.
- 347 34. Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a
348 universal threat to public health? International journal of antimicrobial agents.
349 2008;32(2):106-19.
- 350 35. Mishra DR, Shah DS, Shah N, Prasad JN, Gupta PP, Agrawaal KK. Study of
351 microbiological and antibiotic sensitivity pattern of ventilator associated pneumonia (VAP) in
352 ICU of a tertiary care hospital in Nepal. Journal of family medicine and primary care.
353 2020;9(12):6171.
- 354 36. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a
355 successful pathogen. Clinical microbiology reviews. 2008;21(3):538-82.